Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Retained Earnings (2019 - 2025)

Historic Retained Earnings for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$1.3 billion.

  • Avidity Biosciences' Retained Earnings fell 6952.19% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 6952.19%. This contributed to the annual value of -$893.1 million for FY2024, which is 5646.85% down from last year.
  • Per Avidity Biosciences' latest filing, its Retained Earnings stood at -$1.3 billion for Q3 2025, which was down 6952.19% from -$1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Retained Earnings peaked at -$90.4 million during Q1 2021, and registered a low of -$1.3 billion during Q3 2025.
  • Its 5-year average for Retained Earnings is -$537.9 million, with a median of -$458.0 million in 2023.
  • As far as peak fluctuations go, Avidity Biosciences' Retained Earnings crashed by 20066.71% in 2021, and later plummeted by 5496.32% in 2024.
  • Over the past 5 years, Avidity Biosciences' Retained Earnings (Quarter) stood at -$184.5 million in 2021, then crashed by 94.28% to -$358.5 million in 2022, then plummeted by 59.19% to -$570.8 million in 2023, then tumbled by 56.47% to -$893.1 million in 2024, then crashed by 50.11% to -$1.3 billion in 2025.
  • Its Retained Earnings was -$1.3 billion in Q3 2025, compared to -$1.2 billion in Q2 2025 and -$1.0 billion in Q1 2025.